PMID- 20102778
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20220330
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 117
IP  - 1
DP  - 2010 Apr
TI  - Activation of mTOR signaling pathway contributes to survival of cervical cancer 
      cells.
PG  - 103-8
LID - 10.1016/j.ygyno.2009.12.020 [doi]
AB  - OBJECTIVES: The mammalian target of rapamycin (mTOR) pathway is activated in a 
      range of malignant cancers, but its role in human cervical cancer has not been 
      well defined. This study aims to investigate the activation of mTOR pathway in 
      cervical carcinomas and whether inhibition of mTOR with rapamycin, as well as 
      specific siRNA, could lead to decreased proliferation, induced cell cycle arrest 
      and apoptosis. METHODS: A cervical cancer tissue microarray was tested for 
      activation of the mTOR pathway. The effects on HeLa cell survival and downstream 
      signaling were determined following mTOR inhibition by increasing doses of 
      rapamycin, or silencing by siRNA. RESULTS: The mTOR pathway is activated in 
      cervical carcinomas. mTOR-specific siRNA effectively suppressed HeLa cell growth 
      through mechanisms including inhibition of the cell cycle and increased 
      apoptosis, which were similar to the mechanisms of rapamycin action. CONCLUSION: 
      The mTOR signaling pathway is activated in cervical carcinomas. Inhibition of 
      mTOR represents a potential therapeutic strategy for cervical cancers.
CI  - Copyright 2009 Elsevier Inc. All rights reserved.
FAU - Ji, Jing
AU  - Ji J
AD  - Department of Reproductive Medicine, First Affiliated Hospital of Medical College 
      of Xi'an Jiaotong University, Xi'an, China.
FAU - Zheng, Peng-Sheng
AU  - Zheng PS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100127
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Q20Q21Q62J (Cisplatin)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis/drug effects/physiology
MH  - Cell Cycle/drug effects/physiology
MH  - Cell Survival/drug effects/physiology
MH  - Cisplatin/pharmacology
MH  - Down-Regulation
MH  - Female
MH  - HeLa Cells
MH  - Humans
MH  - Immunohistochemistry
MH  - Intracellular Signaling Peptides and Proteins/antagonists & 
      inhibitors/*metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Protein Serine-Threonine Kinases/antagonists & 
      inhibitors/biosynthesis/*metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - RNA, Small Interfering/genetics
MH  - Signal Transduction/drug effects
MH  - Sirolimus/pharmacology
MH  - TOR Serine-Threonine Kinases
MH  - Uterine Cervical Neoplasms/drug therapy/*metabolism/pathology
EDAT- 2010/01/28 06:00
MHDA- 2010/03/31 06:00
CRDT- 2010/01/28 06:00
PHST- 2009/10/06 00:00 [received]
PHST- 2009/12/15 00:00 [accepted]
PHST- 2010/01/28 06:00 [entrez]
PHST- 2010/01/28 06:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - S0090-8258(09)01021-X [pii]
AID - 10.1016/j.ygyno.2009.12.020 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2010 Apr;117(1):103-8. doi: 10.1016/j.ygyno.2009.12.020. Epub 2010 
      Jan 27.